TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Clinical Trial Information
Trial Contact: Walton, Sherri; Manchola-Orozco, Carolina
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
Male ≥ 18 years of age Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)Evidence of disease progression after prior therapy for mCRPCMolecular evidence of mCRPC associated with HRD